
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
4G Clinical has announced the launch of a Direct-to-Patient (DtP) clinical trial platform, offering sponsors the flexibility to ship drug from the sites to the patient's home. In the midst of the COVID-19 pandemic, clinical trial models are shifting towards DtP to address patient safety & access to trial sites, site capacity challenges, and supply chain disruption.
For more information, click






